Choueiri, T. K.,
Powles, T.,
Peltola, K.,
de Velasco, G.,
Burotto, M.,
Suárez, C.,
Ghatalia, P.,
Iacovelli, R.,
Lam, E. T.,
Verzoni, E.,
Gümüş, M.,
Stadler, W. M.,
Kollmannsberger, C.,
Melichar, B.,
Venugopal, B.,
Gross-Goupil, M.,
Poprach, A.,
De Santis, M.,
Schutz, F. A.,
Park, S. H.,
Nosov, D.,
Porta, C.,
Lee, J. L.,
Garcia-del-Muro, X.,
Biscaldi, E.,
Manneh Kopp, R.,
Oya, M.,
He, L.,
Wang, A.,
Perini, R. F.,
Vickery, D.,
Albiges, L.,
Rini, B. I.,
LITESPARK-005 Investigators:
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
N. Engl. J. Med. 391 (8), 710-721, 2024.
Szarvas, T.,
Varadi, M.,
Horváth, O.,
Soós, E.,
Fazekas, T.,
Csizmarik, A.,
Németh, B.,
Győrffy, B.,
Kenessey, I.,
Reis, H.,
Koll, F.,
Oláh, C.,
Hadaschik, B.,
Krafft, U.,
Mairinger, F.,
Wessolly, M.,
Hoffmann, M.,
Grunewald, C. M.,
Niegisch, G.,
Maráz, A.,
Kuthi, L.,
Furka, A.,
Nyirády, P.:
Combined analysis of molecular patterns and clinical factors for the prediction of immune checkpoint inhibitor therapy in advanced urothelial carcinoma.
Eur. Urol. Suppl. 85 (Suppl.), S215-216, 2024.
Koshkin, V. S.,
Danchaivijitr, P.,
Bae, W. K.,
Semenov, A.,
Ozyilkan, O.,
Su, Y. L.,
Arranz Arija, J.,
Tsujihata, M.,
Bögemann, M.,
Hendriks, M. P.,
Delgado, S. N.,
Rosenbaum, E.,
Lopez, K. A.,
Bavle, A.,
Liu, C. C.,
Imai, K.,
Furka, A.:
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
Eur. Urol. [Epub ahead of print], 2024.
Salazar Soler, R.,
Santos Vivas, C.,
Macias, I.,
Yubero Esteban, A.,
Bassam, A.,
Gallego Plazas, J.,
Al-Farhat, Y.,
Cervantes, A.,
García Alfonso, P.,
Paez, D.,
Ruiz-Casado, A.,
Lopez, C.,
Árkosy, P.,
Furka, A.,
Rodriguez-Salas, N.,
Ramos Pascual, F. J.,
Cubillo Gracian, A.,
Hitre, E.,
Ferreiro Monteagudo, R.,
Salud Salvia, M. A.:
Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study.
Ann. Oncol. 35 (S1), S6, 2024.
Bardia, A.,
Hu, X.,
Dent, R.,
Yonemori, K.,
Barrios, C. H.,
O'Shaughnessy, J. A.,
Wildiers, H.,
Pierga, J. Y.,
Zhang, Q.,
Saura, C.,
Biganzoli, L.,
Sohn, J. H.,
Im, S. A.,
Lévy, C.,
Jacot, W.,
Begbie, N.,
Ke, J.,
Patel, G.,
Curigliano, G.,
DESTINY-Breast06 Trial Investigators:
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
N. Engl. J. Med. 391 (22), 2110-2122, 2024.
Tornyi, I.,
Árkosy, P.,
Horváth, I.,
Furka, A.:
A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with "bone-only" metastatic breast cancer.
Pathol. Oncol. Res. 29, 1-8, (article identifier: 1611369), 2023.
Koshkin, V. S.,
Danchaivijitr, P.,
Bae, W. K.,
Semenov, A.,
Özyilkan, Ö.,
Su, Y. L.,
Arranz Arija, J.,
Tsujihata, M.,
Boegemann, M.,
Hendriks, M. P.,
Neciosup Delgado, S. P.,
Cheng, S.,
Rosenbaum, E.,
Lopez, K. A.,
Bavle, A.,
Liu, C. C.,
Imai, K.,
Furka, A.:
Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment.
Ann. Oncol. 34 (S2), S1211, 2023.
Váradi, M.,
Horváth, O.,
Módos, O.,
Fazekas, T.,
Grunewald, C. M.,
Niegisch, G.,
Krafft, U.,
Grünwald, V.,
Hadaschik, B.,
Oláh, C.,
Maráz, A.,
Furka, A.,
Szűcs, M.,
Nyirády, P.,
Szarvas, T.:
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.
Sci. Rep. 13, 1-11, (article identifier: 17378), 2023.
Furka, A.,
Nagy, Z.,
Szabó, I.,
Fekete, G.,
Kelemen, Á.,
Bolobás, G.,
Sebők, G.,
Molnár, T.,
Árvai, J.,
Tornyi, I.,
Kostyál, L.,
Révész, J.,
Hauser, P.:
Full Body Surface Coverage with Water-Equivalent Bolus as Novel Technique for Total Body Irradiation before Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoid Leukemia.
Children. 9 (11), 1-10, (article identifier: 1740), 2022.
Furka, A.,
Simkó, C.,
Kostyál, L.,
Szabó, I.,
Valikovics, A.,
Fekete, G.,
Tornyi, I.,
Oross, E.,
Révész, J.:
Treatment Algorithm for Cancerous Wounds: a Systematic Review.
Cancers (Basel). 14 (5), 1-12, (article identifier: 1203), 2022.